Free Daily Podcast Summary
Oncology for the Inquisitive Mind: Daily Summaries Delivered
by Michael Fernando and Josh Hurwitz
Cancer is a fascinating but rapidly evolving discipline - it's a full-time job just keeping up to date. In this podcast, Dr Michael Fernando and Dr Joshua Hurwitz explore the latest trials, research, and practice-changing updates, as well as regular interviews with renowned oncology specialists. Ideal for those starting their training journey, established specialists and anyone interested in medical science, oncological practice, or terrible jokes. Preferably all three.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 1 weeks ago34 min
214. Dr Narjust Florez and the rise of early onset lung cancer
Our guest today is someone whose work touches almost every corner of oncology: from the exam room to the lab to the systems we work within.Dr Narjust Florez, MD, FASCO, is a thoracic medical oncologist at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, where she treats young patients and women with lung cancer and leads a research program spanning early diagnosis, clinical trials, and cancer health disparities. She's the Associate Director of the Cancer Care Equity Program and leads the EQUAL Study, which tackles disparities in lung cancer screening among Hispanic and East Asian patients. She's also become one of the most influential voices on physician wellness and burnout in oncology, and on building a more equitable path for women and underrepresented trainees in the field — work that's earned her recognition as the youngest Fellow ever named to the Association for Clinical Oncology, and a spot as JAMA Oncology's first Latina Associate Editor for Diversity, Equity, and Inclusion.Please welcome Dr Narjust Florez.For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners, Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
- 2 weeks ago28 min
213. Back to Basics - Early Melanoma
In this episode, Michael and Josh delve into the world of early melanoma. Some may think that melanoma has had its moment in the sun (pun slightly intended) and that other cancer treatments are passing it by. But in this instance, you can teach an old dog new tricks, an old immunotherapy dog, to be precise. In addition, one of today's studies has Michael's favourite design of any trial: see if you can figure out which one!Studies Discussed in Today's EpisodeKEYNOTE-054NADINAFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
- 3 weeks ago24 min
212. Back to Basics - Non-Melanoma Skin Cancer
If you like cemiplimab, you will like this episode. Since its introduction, cemiplimab has become the mainstay of treatment for cutaneous SCC, the most common non-melanoma skin cancer likely to attend an oncologist. Cemiplimab's scope is expanding; once reserved purely for the locally advanced or metastatic setting, evidence is emerging for its efficacy in the neoadjuvant setting. Today, Josh and Michael explore the use cases for cemiplimab in cSCCNOTE: this episode was NOT sponsored by cemiplimab!Studies Discussed in Today's EpisodeMigden et al. (2018)Gross et al (2023)For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
- 4 weeks ago26 min
211. Back to Basics - Hepatocellular Carcinoma
For over a decade, sorafenib remained unchallenged as first-line therapy for hepatocellular carcinoma, based on the SHARP trial, which showed survival increasing from 7.9 to 10.7 months. This demonstrated modest efficacy in a disease notoriously resistant to systemic treatment. That drought broke in 2020, when IMbrave150 demonstrated that atezolizumab plus bevacizumab beat sorafenib outright, pushing median survival past 19 months and putting immunotherapy on the map for liver cancer. Two years later, HIMALAYA proved that a single priming dose of anti-CTLA-4 could unlock durable responses, with the STRIDE regimen nearly doubling five-year survival compared with sorafenib. Then IMbrave050 asked whether that success could move earlier, into the adjuvant setting after resection — and the early promise didn’t hold up on longer follow-up. Together, these three trials mark both immunotherapy’s arrival in liver cancer and the limits of assuming it translates cleanly across settings.Trials Discussed on Today's Episode:HIMALAYA TrialIMbrave 050IMbrave 150For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
- Aug 15, 202622 min
210. Back to Basics - Biliary Tract Cancers
Until recently, biliary tract cancers were relegated to orphan cancer status: rare cancers such as cholangiocarcinoma and gallbladder cancers. These aggressive malignancies were lumped together, historic trials were small, and patients were stuck with gemcitabine-cisplatin chemotherapy as the only real option, a regimen that hadn't changed for almost a decade. Then two trials cracked the field open. BILCAP, reported in 2019, gave resected patients their first evidence-based reason to take adjuvant capecitabine, pushing median survival from around three years to over four. And in 2022, TOPAZ-1 became the first trial to prove immunotherapy has a place in biliary cancer. Durvalumab was added to standard chemo, and in the latest three-year follow-up, it cut the risk of death by over a quarter. Together, these two trials didn't just add drugs to a protocol; they turned biliary tract cancer from an afterthought into a disease with modern treatment pathways.Trials Discussed on Today's Episode:BILCAPTOPAZ-1For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
- Aug 8, 20261h 7m
209. Interview with Dr Kerry Jewell
On today's episode, we have a very special guest: Dr Kerry Jewell is a nuclear medicine physician, medical advocate and very good friend of the show, who recently published her debut novel A Little Unwell. Kerry is wonderfully eloquent doctor who frequently chooses violence when with dealing with Michael, whom she has known for his entire medical career. Today, Kerry discusses her book, working as a nuclear medicine physician, provides some of her amazing wisdom for our oncology colleagues and gets candid about a recent, heart-breaking diagnosis. A Little Unwell available here: https://www.amazon.com.au/Little-Unwell-Kerry-Jewell/dp/0733653952*This is not an affiliate link. We just think the book is great!For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
- Jul 12, 202652 min
208. ASCO 2026 - The Plenary Episode - Part 3
This episode is the ASCO 2026 Plenary Episode. This week, all of the pivotal, game-changing, life-changing trials are discussed here. Some describe the plenary session as practice-changing, and we will always agree that better treatments with significant improvements in life expectancy and quality of life need their time in the spotlight.Today, five trials are discussed, including SARC041, a liposarcoma study utilising the CDK 4/6 inhibigtor abemacicilib. Our second study is HARMONI-6, investigating whether ivonescimab plus chemotherapy is effective in patients with advanced squamous non-small cell lung cancer. Our third, almost like something written for an opera (LIBRETTO0-432), a lung cancer trial looking at selpercatinib in those with RET fusion early-stage NSCLCa. PROTEUS emerges as our fourth trial, rising from the depths of the ocean to evaluate apalutamide in the perioperative prostate cancer space.Finally, and most importantly in our opinion, is RASolute302, the pancreatic cancer trial, showing that even the most difficult mutation is now treatable. An incredible story of an exceptionally difficult cancer to treat, Daraxonrasib is the star of this year's ASCO.Studies Discussed in this EpisodeSARC041HARMONI-6LIBRETTO0-432PROTEUSRASolute302For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
- Jul 5, 20261h 4m
207. ASCO 2026 - Agents of the Future - Part 2
This week, Josh and Michael's ASCO 2026 coverage looks at "Agents of the Future", trials of intrigue, promise and potential beyond its status. This episode also sheds light on more orphan status cancers like head and neck cancer, basket cohort studies, resistant EGFR lung cancer, metastatic colorectal cancer and hepatocellular carcinoma.One more episode left of this arc - The Plenary! Stay tuned.Studies Discussed in this EpisodeOrigAMI-4 WU-KONG28A Phase 1/2 Study of JK06, a 5T4-Targeted Antibody Drug Conjugate (ADC), In Patients with Unresectable Locally Advanced or Metastatic CancerESANOAROSETTA Lung-02Ivonescimab + FOLFOXHERIZON-CRC01CIRCULATEEMERALD-3BLUESTARGLP-1 agonist in breast cancer (Palleschi et al)For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
Get Oncology for the Inquisitive Mind summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
Out of the Gray (Gy) - Standard Imaging
Conversations with experts in radiation oncology exploring advancements in technology, research, and clinical practice.
The Curbsiders Internal Medicine Podcast
Expert-led internal medicine discussions with clinical insights and humor for primary care and hospital medicine providers.
Jon Holmes Says the C-Word
A man discusses his cancer experience with guests, sharing honest and often humorous stories about diagnosis and treatment.
The Dr. Gabrielle Lyon Show
Discusses health, longevity, and mental resilience through science-based conversations with medical and wellness experts.
Inquiring Minds
Explores the intersection of science and society through critical thinking and in-depth analysis.
Paul Saladino MD podcast
A physician explores the root causes of chronic disease and optimal health through science and personal experimentation.
The Peter Attia Drive
Conversations with experts on health, longevity, performance, and critical thinking led by physician Peter Attia.
Red Pill Your Healthcast
Two healthcare providers discuss overlooked health issues and empower listeners to make informed decisions for their families.
The Evolving Wellness Podcast with Sarah Kleiner Wellness
Explores circadian rhythms, hormone balance, nutrition, and quantum health through science-based insights for sustainable wellness.
Health Discovered
Doctors explore surprising stories to uncover insights about health and well-being.
The Exam Room by the Physicians Committee
Experts reveal how plant-based diets and nutrition science can prevent disease and extend lifespan.
The Dr. Josh Axe Show
Explores natural health, nutrition, emotional resilience, and personal growth through expert insights and practical strategies.
About Oncology for the Inquisitive Mind
Cancer is a fascinating but rapidly evolving discipline - it's a full-time job just keeping up to date. In this podcast, Dr Michael Fernando and Dr Joshua Hurwitz explore the latest trials, research, and practice-changing updates, as well as regular interviews with renowned oncology specialists. Ideal for those starting their training journey, established specialists and anyone interested in medical science, oncological practice, or terrible jokes. Preferably all three.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from Oncology for the Inquisitive Mind in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's Oncology for the Inquisitive Mind daily summary?
It's a free AI-powered email that summarizes new episodes of Oncology for the Inquisitive Mind as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the Oncology for the Inquisitive Mind podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official Oncology for the Inquisitive Mind product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Michael Fernando and Josh Hurwitz.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does Oncology for the Inquisitive Mind release new episodes?
Oncology for the Inquisitive Mind publishes weekly. Our AI generates a summary within hours of each new episode.
What topics does Oncology for the Inquisitive Mind cover?
Oncology for the Inquisitive Mind covers topics including Science, Education, Medicine, Fitness, Health & Fitness, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting Oncology for the Inquisitive Mind summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.